Prevalence of anticipatory nausea and vomiting in breast cancer patients undergoing highly emetogenic chemotherapy.
Rafaela de Brito AlvesCamilla Vieira de RebouçasAlayne Magalhães Trindade Domingues YamadaFelipe Cavalcanti Carneiro da SilvaPublished in: Revista da Associacao Medica Brasileira (1992) (2024)
The prevalence of anticipatory nausea is still high in the era of neurokinin-1 antagonists, and failure of antiemetic control in C1 remains the main risk factor. All efforts should be made to control chemotherapy-induced nausea or nausea and vomiting on C1 to avoid anticipatory nausea.